Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK

by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.

You can read our English Press Release, clicking here:

Oblique Therapeutics together with collaborators at Sahlgrenska University Hospital and Karolinska Institutet has been granted 5MSEK by Vinnova.